Target intelligence / Profile preview

Cyclic GMP-AMP synthase (cGAS) (cGAS)

Target
cGAS
Molecular classification
Enzyme, Transferase, Nucleotidyltransferase, Pattern recognition receptor
01

Overview

Cyclic GMP-AMP synthase (cGAS), encoded by the MB21D1 gene, is a critical cytosolic pattern recognition receptor and nucleotidyltransferase enzyme that acts as a primary sensor of double-stranded DNA (dsDNA) in the cytoplasm. Upon binding to aberrant cytosolic DNA—which can originate from viral or bacterial pathogens, or from self-DNA leaked due to cellular damage, genomic instability, or mitochondrial dysfunction—cGAS catalyzes the synthesis of the second messenger cyclic GMP-AMP (cGAMP) from ATP and GTP. cGAMP subsequently binds to and activates the stimulator of interferon genes (STING) adaptor protein, triggering a signaling cascade that leads to the production of type I interferons and pro-inflammatory cytokines.

While this pathway is essential for host defense against infections and tumor surveillance, chronic or aberrant activation of cGAS by self-DNA is a major driver of autoimmune and autoinflammatory diseases, such as systemic lupus erythematosus (SLE), Aicardi-Goutières syndrome (AGS), and various age-related inflammatory and neurodegenerative disorders. Consequently, cGAS has emerged as a highly attractive therapeutic target. Small-molecule cGAS inhibitors, such as VENT-03 and IMSB301, are currently in clinical development to suppress pathologic type I interferon signaling and treat autoimmune and inflammatory conditions.

Other names
MB21D1C6orf150Mab-21 domain-containing protein 1h-cGAScGAMP synthase2'3'-cGAMP synthase
02

Mechanism of action

Inhibition of cyclic GMP-AMP (cGAMP) synthesis by blocking cGAS enzymatic activity

03

Biological functions

Innate immune responseDNA sensingType I interferon productionCellular senescenceAutophagyInflammatory response
04

Disease associations

Autoimmune diseaseInflammationCancerNeurodegenerative diseaseInfectionCardiovascular disease
05

Safety considerations

Theoretical risk of viral reactivationSuppression of innate immunityImpaired defense against DNA/RNA virusesPotential for systemic immunosuppression
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Interferon-stimulated gene (ISG) signatureType I interferon levelscGAMP levelsCytosolic double-stranded DNA (dsDNA)Phosphorylated IRF3CXCL10 levelsIFN-beta levels

Beyond the preview

Go deeper on Cyclic GMP-AMP synthase (cGAS) (cGAS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic GMP-AMP synthase (cGAS) (cGAS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call